- Question
- Does olezarsen, an antisense oligonucleotide targeting apolipoprotein C-III mRNA, lower triglycerides in patients with moderate hypertriglyceridemia and elevated cardiovascular risk?
- Design
- Phase 3, international, double-blind, randomized, placebo-controlled trial. Patients were assigned 1:3 to a 50-mg or 80-mg cohort and then, within each cohort, 3:1 to olezarsen or placebo. The registry reports 1478 patients randomized; the primary efficacy analysis included 1349.
- Population
- Patients with moderate hypertriglyceridemia (triglycerides 150 to 499 mg/dL) and elevated cardiovascular risk, or with severe hypertriglyceridemia (triglycerides ≥500 mg/dL). Median age was 64 years, 40% were women, and median baseline triglycerides were 238.5 mg/dL.
- Intervention
- Monthly subcutaneous olezarsen at a dose of 50 mg or 80 mg.
- Control
- Matching monthly subcutaneous placebo.
- Primary outcome
- Least-squares mean percent change in triglyceride level from baseline to 6 months among patients with moderate hypertriglyceridemia, reported as the placebo-adjusted difference for each olezarsen dose.
- Results
- At 6 months, the placebo-adjusted change in triglycerides was -58.4 percentage points (95% CI, -65.1 to -51.7; P<0.001) with 50 mg and -60.6 percentage points (95% CI, -67.1 to -54.0; P<0.001) with 80 mg.
- Safety
- The incidence of serious adverse events appeared similar across the trial groups.
- Conclusion
- In patients with moderate hypertriglyceridemia and elevated cardiovascular risk, olezarsen produced a significantly greater triglyceride reduction at 6 months than placebo.
- Why it matters
- It provides an APOC3-targeted antisense therapy with a very pronounced triglyceride-lowering effect in a population at elevated cardiovascular risk, where highly effective options were lacking. Whether this translates into fewer clinical cardiovascular events remains to be established in dedicated outcome trials.
Card generated automatically with AI from the abstract of the original publication and the trial registry; every figure was checked against those sources. It may contain errors: verify the data at the source before using it for clinical decisions.
Generated on October 18, 2026